There Are Only 3 Ways To Increase Your IGF-1 (How To Pick The Right One)
Your pituitary gland releases growth hormone in pulses, and those pulses travel through your bloodstream to your liver, where the liver converts them into something called IGF-1, which stands for insulin-like growth factor 1 and is the molecule that actually drives most of the muscle growth, fat loss, and recovery that people associate with growth hormone. That conversion step is the whole system. And every compound on the market, whether it is a peptide or pharmaceutical HGH or direct IGF-1, is just targeting a different point in that chain.
That map matters because it is exactly why stacking does not work the way most people think it does, and why the compound that sounds the most powerful is not always the right one.
The first category works at the top of the chain. Compounds like Tesamorelin, CJC-1295, and Sermorelin belong to a class called GHRH analogs, which are synthetic versions of the signal your hypothalamus already sends to tell your pituitary to release growth hormone. When you inject one of these, you are not adding anything foreign to the system. You are amplifying an instruction that already exists.
The system responds, but it also self-corrects. When IGF-1 rises high enough, your brain releases something called somatostatin, which is essentially a brake signal that tells the pituitary to stop. This is called negative feedback, and it is the reason GHRH analogs have a ceiling. Your body will not let IGF-1 climb past a point it considers safe, no matter how much of the peptide you inject.
That ceiling is not a flaw. It is the mechanism that makes this category the most forgiving. The Tesamorelin trials measured visceral fat reduction specifically because that is the population the studies enrolled, but the fat loss mechanism is just GH-mediated lipolysis, which is growth hormone binding to receptors on fat cells and signaling them to release stored fatty acids into circulation. Visceral fat has a higher density of growth hormone receptors than subcutaneous fat, so it responds first and most strongly, and that is true whether the GH comes from Tesamorelin or anything else. The 2007 Falutz trial in the New England Journal of Medicine showed 15.2 percent reduction in trunk fat over 26 weeks with Tesamorelin in HIV patients with lipodystrophy, and the 2015 Stanley and Grinspoon review confirmed the mechanism extends beyond that population.
The second category skips the pituitary entirely. Pharmaceutical HGH is exogenous growth hormone, meaning you are injecting the hormone itself rather than a signal to produce it. Because the signal is coming from outside the feedback loop, your IGF-1 can climb past your natural ceiling, and your liver will convert that exogenous GH into IGF-1 the same way it would convert endogenous GH.
The trade-off is that your pituitary notices. When exogenous GH is present, the pituitary reads it as a sign that there is already enough GH in circulation, and it dials back its own output. The Rosenthal study from 1986 showed that exogenous GH directly suppresses the pituitary's response to GHRH, which is exactly why adding a GHRH analog on top of pharmaceutical HGH is paying for a signal the pituitary is not listening to anymore. Hashimoto et al. demonstrated the same suppressive mechanism even with the 20K variant of GH. The pituitary suppression is the feedback loop working as designed, just against you in this case.
This is also why exogenous HGH requires ongoing bloodwork. Without your own feedback loop functioning as a regulator, IGF-1 levels depend entirely on how much you inject and how your liver responds, and those numbers need to be tracked directly.
The third category removes all the middlemen. IGF-1 LR3 is a modified form of IGF-1 that you inject directly, so you are not stimulating GH, you are not waiting for the liver to do any conversion, you are delivering the endpoint of the entire chain in one step. LR3 refers to a structural modification that extends the half-life and reduces binding to proteins that would otherwise blunt its activity, which makes it substantially more potent than natural IGF-1.
That potency is also why it has to be cycled. The receptors that IGF-1 binds to will downregulate with continuous exposure, meaning they pull back from the cell surface and become less responsive, which is the body's way of protecting itself from chronic overstimulation. The practical window before receptor desensitization becomes a significant problem is roughly six to eight weeks. Chapman et al. showed that even endogenous IGF-1 elevation is enough to suppress GH release through negative feedback, which means IGF-1 LR3 is operating on the same feedback architecture, just further downstream.
The stacking question comes up constantly because the logic seems right on the surface: more signals should mean more output. But the feedback system does not add signals, it weighs them. If your pituitary is suppressed by exogenous HGH, a GHRH analog does nothing. If your IGF-1 is already elevated from pharmaceutical HGH, adding IGF-1 LR3 does not multiply the effect, it just increases receptor load and systemic IGF-1 burden without a proportional return.
The Johannsson study from 1997 gives a useful reference point for what GH-mediated fat loss actually looks like in practice: abdominally obese men on GH treatment lost abdominal fat mass over nine months, but also saw changes in glucose and lipoprotein metabolism, which is a reminder that this system does not operate in isolation. Insulin sensitivity shifts, lipid profiles shift, and IGF-1 is not a switch you flip in one direction without the rest of the metabolic picture moving with it.
None of these compounds reliably produce fat loss without a calorie deficit. GH-mediated lipolysis releases fatty acids into circulation, but if you are eating at maintenance or above, those fatty acids get reesterified and stored again. The mechanism only completes if the fatty acids are actually burned for energy, and that requires the context of a deficit.
The right compound is not the most powerful one. It is the one that matches what your system can actually do with the signal, and understanding the chain tells you exactly where your bottleneck is.
References
- Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 357(23):2359-70. DOI: 10.1056/NEJMoa072375
- Stanley TL, Grinspoon SK. (2015). Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies. Growth Horm IGF Res 25(2):59-65. DOI: 10.1016/j.ghir.2014.12.005
- Moller N, Jorgensen JO. (2009). Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 30(2):152-77. DOI: 10.1210/er.2008-0027
- Hashimoto Y, Kamioka T, Hosaka M, Mabuchi K, Mizuchi A, Shimazaki Y, Tsunoo M, Tanaka T. (2000). Exogenous 20K growth hormone (GH) suppresses endogenous 22K GH secretion in normal men. J Clin Endocrinol Metab 85(2):601-6. DOI: 10.1210/jcem.85.2.6377
- Rosenthal SM, Hulse JA, Kaplan SL, Grumbach MM. (1986). Exogenous growth hormone inhibits growth hormone-releasing factor-induced growth hormone secretion in normal men. J Clin Invest 77(1):176-83. DOI: 10.1172/JCI112273
- Chapman IM, Hartman ML, Pieper KS, Skiles EH, Pezzoli SS, Hintz RL, Thorner MO. (1998). Recovery of growth hormone release from suppression by exogenous insulin-like growth factor I: evidence for a suppressive action of free rather than bound IGF-I. J Clin Endocrinol Metab 83(8):2836-42. DOI: 10.1210/jcem.83.8.5040
- Johannsson G, Marin P, Lonn L, Ottosson M, Stenlof K, Bjorntorp P, Sjostrom L, Bengtsson BA. (1997). Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab 82(3):727-34. DOI: 10.1210/jcem.82.3.3809
Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness
If this is the kind of information you want access to on a daily basis, the community is free and there are full courses on training, nutrition, hormones, and supplementation inside. You can ask questions and post your own labs and get feedback from me and from the community.